Skip to main content

Table 2 Relative risks for discontinuation due to adverse events (medicine vs. placebo)

From: Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran

Treatment

Relative risk (95.0% CI)

Placebo risk (95.0% CI)

LDX

3.21 (0.93–7.90)

0.0443 (0.035–0.053)

ATX

2.67 (1.68–4.13)

 

MPH-ER

2.76 (1.83–4.07)

 
  1. LDX Lisdexamfetamine, ATX Atomoxetine, MPH-ER Methylphenidate extended release, CI confidence interval
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000